Uçar M, et al. - The efficacy and safety of intravesical onabotulinum toxin A (onaBoNTA) injections were assessed for the treatment of children diagnosed with refractory overactive bladder (OAB) by using non-invasive methods. Researchers administered intravesical onaBoNTA injection at the dose of 10 U/kg (max: 200 U) to a total of 31 pediatric patients with a mean age of 10.2 years. They noted that for the management of patients with non-neurogenic OAB that is refractory to medical therapy, OnaBoNTA therapy is as an effective and reliable second-line off-label therapy. They suggested completion of a standardized questionnaire form by patients/guardians before and after the therapy as an easy and non-invasive assessment to ascertain the response to the therapy.